Perrigo (NYSE: PRGO) recently received a number of ratings updates from brokerages and research firms:
- 1/14/2025 – Perrigo was downgraded by analysts at Argus from a “buy” rating to a “hold” rating.
- 1/11/2025 – Perrigo was downgraded by analysts at StockNews.com from a “buy” rating to a “hold” rating.
- 1/6/2025 – Perrigo was downgraded by analysts at Piper Sandler from an “overweight” rating to a “neutral” rating. They now have a $27.00 price target on the stock, down previously from $34.00.
- 1/3/2025 – Perrigo was downgraded by analysts at StockNews.com from a “buy” rating to a “hold” rating.
- 12/25/2024 – Perrigo was downgraded by analysts at StockNews.com from a “buy” rating to a “hold” rating.
Perrigo Stock Performance
PRGO stock traded down $0.77 during midday trading on Tuesday, hitting $23.57. The stock had a trading volume of 1,794,229 shares, compared to its average volume of 1,546,861. The company has a current ratio of 2.56, a quick ratio of 1.77 and a debt-to-equity ratio of 0.94. The stock has a 50-day simple moving average of $26.71 and a 200 day simple moving average of $26.80. Perrigo Company plc has a 52 week low of $23.14 and a 52 week high of $33.96. The firm has a market capitalization of $3.22 billion, a price-to-earnings ratio of -20.15 and a beta of 0.53.
Perrigo (NYSE:PRGO – Get Free Report) last issued its earnings results on Wednesday, November 6th. The company reported $0.81 EPS for the quarter, meeting the consensus estimate of $0.81. The company had revenue of $1.09 billion for the quarter, compared to the consensus estimate of $1.12 billion. Perrigo had a negative net margin of 3.64% and a positive return on equity of 7.38%. The firm’s revenue for the quarter was down 3.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.64 EPS. As a group, equities research analysts anticipate that Perrigo Company plc will post 2.56 earnings per share for the current year.
Perrigo Dividend Announcement
Insider Transactions at Perrigo
In related news, Director Jeffrey B. Kindler sold 17,598 shares of the company’s stock in a transaction dated Monday, December 9th. The stock was sold at an average price of $28.27, for a total value of $497,495.46. Following the completion of the sale, the director now owns 5,409 shares in the company, valued at approximately $152,912.43. This represents a 76.49 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 0.70% of the stock is currently owned by corporate insiders.
Hedge Funds Weigh In On Perrigo
Several institutional investors and hedge funds have recently modified their holdings of the business. Wealth Enhancement Advisory Services LLC boosted its position in shares of Perrigo by 2.1% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 21,617 shares of the company’s stock worth $567,000 after buying an additional 436 shares during the period. Voisard Asset Management Group Inc. boosted its position in Perrigo by 9.7% during the 3rd quarter. Voisard Asset Management Group Inc. now owns 5,100 shares of the company’s stock worth $134,000 after acquiring an additional 450 shares during the last quarter. Central Pacific Bank Trust Division boosted its position in Perrigo by 33.3% during the 4th quarter. Central Pacific Bank Trust Division now owns 2,000 shares of the company’s stock worth $51,000 after acquiring an additional 500 shares during the last quarter. Creative Planning raised its holdings in shares of Perrigo by 3.7% in the third quarter. Creative Planning now owns 18,477 shares of the company’s stock valued at $485,000 after purchasing an additional 661 shares during the last quarter. Finally, KBC Group NV lifted its position in shares of Perrigo by 25.1% in the third quarter. KBC Group NV now owns 4,517 shares of the company’s stock worth $118,000 after purchasing an additional 905 shares in the last quarter. 95.91% of the stock is currently owned by institutional investors and hedge funds.
Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers.
Featured Articles
- Five stocks we like better than Perrigo
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- The Fed Is More Likely to Hike Than Cut Rates in 2025
- What Are Some of the Best Large-Cap Stocks to Buy?
- Investors Navigate Uncertainty by Seeking Refuge in Gold and Oil
- How to Use Stock Screeners to Find Stocks
- Archer Aviation Shares Slide, Now Bargain Priced for 2025
Receive News & Ratings for Perrigo Company plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perrigo Company plc and related companies with MarketBeat.com's FREE daily email newsletter.